New Pancreatic Cancer Trial Explores Innovative KRAS-Targeted Immunotherapy Strategy

A New Horizon in Pancreatic Cancer Treatment

The Lustgarten Foundation, in collaboration with Break Through Cancer, has embarked on an innovative clinical trial aimed at tackling the formidable challenge of pancreatic cancer. This Phase 1 study will evaluate the next-generation KRAS-targeted immunotherapy known as ELI-002 7P. The trial is not only a significant stride in cancer research but a beacon of hope for patients fighting pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of pancreatic cancer.

Study’s Objective and Structure

The focus of this groundbreaking trial is to assess how the unique microenvironment of pancreatic tumors influences the response to a new immune treatment method. Led by respected oncologists Kevin Soares, MD, and Eileen O'Reilly, MD, at Memorial Sloan Kettering Cancer Center, the study will recruit 20 patients diagnosed with resectable or borderline resectable KRAS-mutant pancreatic cancer. This cohort will receive ELI-002 7P alongside standard neoadjuvant mFOLFIRINOX chemotherapy, with or without the PD-1 inhibitor tislelizumab.

The trial aims not only to evaluate the safety and efficacy of the treatment but also to gather detailed molecular and immune data. By analyzing patient samples before and after treatment, researchers hope to glean critical insights into the ways pancreatic tumors—and their surrounding environments—react to the developed therapies.

The Importance of Collaboration

Andrew Rakeman, VP of the Lustgarten Foundation, emphasized the significance of collaborative efforts in advancing cancer treatments. “This trial represents a fusion of innovative immunotherapy and comprehensive analyses of the tumor microenvironment,” he noted. The combined expertise of the research team, which includes six leading cancer centers—Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MIT's Koch Institute for Integrative Cancer Research, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The University of Texas MD Anderson Cancer Center, and NYU Langone Health—creates a powerful platform for dissecting the complexities of pancreatic tumors and enhancing treatment efficacy.

Building on Previous Research

This initiative builds on a Phase 1 clinical trial published in Nature Medicine in 2025, which reported positive immune responses from an earlier version of the KRAS-targeted immunotherapy in patients who had undergone surgery and chemotherapy. By placing ELI-002 7P earlier in the treatment regimen, this study is looking to determine if combining it with chemotherapy could lead to stronger anti-tumor responses and insights into treatment dynamics within the tumor microenvironment.

What’s Next for Participants

The study is actively recruiting patients across multiple Memorial Sloan Kettering Cancer Center locations in New York and New Jersey, with plans to open further sites at Dana-Farber and other institutions. This offers eligible patients a unique opportunity to participate in pioneering research that could transform the landscape of pancreatic cancer treatment. Those interested in enrollment or seeking further details can refer to the ClinicalTrials.gov listing for this trial.

A Vision for the Future

The Lustgarten Foundation is renowned for its contributions as the largest private funder of pancreatic cancer research globally. Its mission focuses on early detection and improved treatment strategies, aiming to turn what is often deemed an incurable disease into a manageable condition. Meanwhile, Break Through Cancer fosters radical cooperation among the top cancer research bodies, establishing a transformative approach to tackling some of the deadliest cancer types.

In conclusion, this trial not only represents a significant forward leap in medical research for pancreatic cancer but also encapsulates a broader vision—an integrated, collaboration-driven strategy to unveil and conquer the complexities of cancer treatment. As research progresses and results materialize, there remains a collective hope that innovations like the KRAS-targeted immunotherapy will usher in a new era of effective cancer therapies.